Literature DB >> 17059794

Operative risk factors in the metabolic syndrome: is it lipids and high blood pressure or are there direct vascular effects of insulin resistance and obesity?

Olavi Ukkola1.   

Abstract

The metabolic syndrome is associated with an increased risk for cardiovascular disease. Dyslipidemia, high blood pressure, and impaired glucose tolerance, components of the metabolic syndrome, are all clearly atherogenic. Insulin resistance is an important correlate of other risk factors. Excess abdominal fat, as often seen in overweight people and commonly observed in obese individuals, is the single most important central feature of the metabolic syndrome. In addition to insulin resistance, an excess amount of abdominal fat is associated with all the features of metabolic clustering. Adipocytes secrete several peptide hormones that have been related to the metabolic syndrome and related cardiovascular disease. The role of traditional versus novel adipose tissue-related risk factors in the background of atherosclerosis in the metabolic syndrome are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059794     DOI: 10.1007/s11886-006-0100-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   3.955


  50 in total

Review 1.  Adipokines: molecular links between obesity and atheroslcerosis.

Authors:  David C W Lau; Bikramjit Dhillon; Hongyun Yan; Paul E Szmitko; Subodh Verma
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-01-14       Impact factor: 4.733

2.  Glucose metabolism in patients with essential hypertension.

Authors:  Juan García-Puig; Luis M Ruilope; Manuel Luque; Jaime Fernández; Rafael Ortega; Rafael Dal-Ré
Journal:  Am J Med       Date:  2006-04       Impact factor: 4.965

Review 3.  Visceral fat and insulin resistance--causative or correlative?

Authors:  K N Frayn
Journal:  Br J Nutr       Date:  2000-03       Impact factor: 3.718

Review 4.  Hypertension and the metabolic syndrome.

Authors:  Stephen A Morse; Rubin Zhang; Vashu Thakur; Efrain Reisin
Journal:  Am J Med Sci       Date:  2005-12       Impact factor: 2.378

5.  Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance.

Authors:  Morvarid Kabir; Karyn J Catalano; Suchitra Ananthnarayan; Stella P Kim; Gregg W Van Citters; Melvin K Dea; Richard N Bergman
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-11-02       Impact factor: 4.310

6.  A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha.

Authors:  Takayoshi Suganami; Junko Nishida; Yoshihiro Ogawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-08-25       Impact factor: 8.311

Review 7.  Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.

Authors:  Jeong-a Kim; Monica Montagnani; Kwang Kon Koh; Michael J Quon
Journal:  Circulation       Date:  2006-04-18       Impact factor: 29.690

8.  Visceral obesity is characterized by impaired nitric oxide-independent vasodilation.

Authors:  S Vigili de Kreutzenberg; E Kiwanuka; A Tiengo; A Avogaro
Journal:  Eur Heart J       Date:  2003-07       Impact factor: 29.983

9.  C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study.

Authors:  Martin K Rutter; James B Meigs; Lisa M Sullivan; Ralph B D'Agostino; Peter W F Wilson
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

10.  The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford
Journal:  Atherosclerosis       Date:  2003-06       Impact factor: 5.162

View more
  1 in total

1.  TyGIS: improved triglyceride-glucose index for the assessment of insulin sensitivity during pregnancy.

Authors:  Benedetta Salvatori; Tina Linder; Daniel Eppel; Micaela Morettini; Laura Burattini; Christian Göbl; Andrea Tura
Journal:  Cardiovasc Diabetol       Date:  2022-10-18       Impact factor: 8.949

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.